WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today reported financial results for the fourth quarter and fiscal year ended December 31, 2006. The Company reported total revenues of $46.2 million for fiscal year 2006, compared to revenues of $23.6 million for fiscal year 2005. During the fourth quarter of 2006, Oscient recorded $12.5 million in revenue from the cardiovascular drug ANTARA® (fenofibrate) capsules and $5.5 million in revenue from the antibiotic FACTIVE ® (gemifloxacin mesylate) tablets. Total revenues for the fourth quarter of 2006 were $18.3 million, nearly double the $9.5 million in total revenues recorded in the fourth quarter of 2005.
